Biologics for chronic spontaneous urticaria: toward a personalized treatment

References

• Grattan CEH, Francis DM, Hide M, et al. Detection of circulating histamine releasing autoantibodies with functional properties of anti-IgE in chronic urticaria. Clin Exp Allergy. 1991;21:695–704.
   PubMed Web of Science ®Google Scholar
• Hide M, Francis DM, Grattan CEH, et al. Autoantibodies against the high-affinity IgE receptor as a cause of histamine release in chronic urticaria. N Engl J Med. 1993;328:1599–1604.
   PubMed Web of Science ®Google Scholar
• Fiebiger E, Maurer D, Holub H, et al. Serum IgG autoantibodies directed against the alpha chain of FcεRI: a selective marker and pathogenetic factor for a distinct subset of chronic urticaria patients? J Clin Invest. 1995;96:2606–2612.
   PubMed Web of Science ®Google Scholar
• Ferrer M, Kinet JP, Kaplan AP. Comparative studies of functional and binding assays for IgG anti-FcεRIα (α-subunit). J Allergy Clin Immunol. 1998;101:672–676.
   PubMed Web of Science ®Google Scholar
• Greaves MW. Chronic urticaria. J Allergy Clin Immunol. 2000;105:664–672.
   PubMed Web of Science ®Google Scholar
• Asero R, Tedeschi A, Lorini M, et al. Chronic urticaria: novel clinical and serological aspects. Clin Exp Allergy. 2001;31:1105–1110.
   PubMed Web of Science ®Google Scholar
• Sabroe RA, Fiebiger E, Francis DM, et al. Classification of anti-FcepsilonRI and anti-IgE autoantibodies in chronic idiopathic urticaria and correlation with disease severity. J Allergy Clin Immunol. 2002;110:492–499.
   PubMed Web of Science ®Google Scholar
• Altrichter S, Peter HJ, Pisarevskaja D, et al. IgE mediated autoallergy against thyroid peroxidase—a novel pathomechanism of chronic spontaneous urticaria? PLoS One. 2011;6(4):e14794.
   PubMed Web of Science ®Google Scholar
• Schmetzer O, Lakin E, Topal FA, et al. IL‐24 is a common and specific autoantigen of IgE in patients with chronic spontaneous urticaria. J Allergy Clin Immunol. 2018;142:876‐82.
   PubMed Web of Science ®Google Scholar
• Asero R, Marzano AV, Ferrucci S, et al. Co-occurrence of IgE and IgG autoantibodies in patients with chronic spontaneous urticaria. Clin Exp Immunol. 2020;200:242–249.
   PubMed Web of Science ®Google Scholar
• Sanchez J, Sanchez A, Cardona R. Causal relationship between anti-TPO IgE and chronic urticaria by in-vitro and in-vivo tests. Allergy Asthma Immunoll Res. 2019;11:29–42.
   PubMed Web of Science ®Google Scholar
• Kolkhir P, Kovalkova E, Chernov A, et al. Autoimmune chronic spontaneous urticaria detection with IgG-anti-TPO and total IgE. J Allergy Clin Immunol Pract. 2021;9:4138–4146.
   PubMed Web of Science ®Google Scholar
• Asero R. Clinical variables of severe chronic spontaneous urticaria from total IgE standpoint: a retrospective study. Eur Ann Allergy Clin Immunol. 2022;50:30–33.
   Google Scholar
• Bossi F, Frossi B, Radillo O, et al. Mast cells are critically involved in serum mediated vascular leakage in chronic urticaria beyond high-affinity IgE receptor stimulation. Allergy. 2011;66:1538–1545.
   PubMed Web of Science ®Google Scholar
• Cugno M, Marzano AV, Tedeschi A, et al. Expression of tissue factor by eosinophils in patients with chronic urticaria. Int Arch Allergy Immunol. 2009;148:170–174.
   PubMed Web of Science ®Google Scholar
• Yanase Y, Takahagi S, Hide M. Chronic spontaneous urticaria and the extrinsic coagulation system. Allergol Int. 2018;67:191–194.
   PubMed Web of Science ®Google Scholar
• Saito R, Yanase Y, Kamegashira A, et al. Increase of tissue factor expression on the surface of peripheral monocytes of patients with chronic spontaneous urticaria. Allergy. 2020;75:971–974.
   PubMed Web of Science ®Google Scholar
• Zuberbier T, Abdul Latiff AH, Abuzakouk M, et al. The international EAACI/GA2LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy. 2022;77:734–766.
   PubMed Web of Science ®Google Scholar
• Tharp MD, Bernstein JA, Kavati A, et al. Benefits and harms of omalizumab treatment in adolescent and adult patients with chronic idiopathic (Spontaneous) urticaria: a meta-analysis of “Real-world” Evidence. JAMA Dermatol. 2019;155:29–38.
   PubMed Web of Science ®Google Scholar
• Zhao ZT, Ji CM, Yu WJ, et al. Omalizumab for the treatment of chronic spontaneous urticaria: a meta-analysis of randomized clinical trials. J Allergy Clin Immunol. 2016;137:1742–1750.
   PubMed Web of Science ®Google Scholar
• Marzano AV, Genovese G, Casazza G, et al. Predictors of response to omalizumab and relapse in chronic spontaneous urticaria: a study of 470 patients. J Eur Acad Dermatol Venereol. 2019;33:918–924.
   PubMed Web of Science ®Google Scholar
• Ertas R, Ozyurt K, Atasoy M, et al. The clinical response to omalizumab in chronic spontaneous urticaria patients is linked to and predicted by IgE levels and their change. Allergy. 2018;73:705–712.
   PubMed Web of Science ®Google Scholar
• Weller K, Ohanyan T, Hawro T, et al. Total IgE levels are linked to the response of chronic spontaneous urticaria patients to omalizumab. Allergy. 2018;73:2406–2408.
   PubMed Web of Science ®Google Scholar
• Straesser MD, Oliver E, Palacios T, et al. Serum IgE as an immunological marker to predict response to omalizumab treatment in symptomatic chronic urticaria. J Allergy Clin Immunol Pract. 2018;6:1386–1388.
   PubMed Web of Science ®Google Scholar
• Nettis E, Cegolon L, Di Leo E, et al. Omalizumab in chronic spontaneous urticaria: efficacy, safety, predictors of treatment outcome, and time to response. Ann Allergy Asthma Immunol. 2018;121:474–478.
   PubMed Web of Science ®Google Scholar
• Asero R. Chronic spontaneous urticaria treated with Omalizumab: what differentiates early from late responders? Eur Ann Allergy Clin Immunol. 2021;53(1):47–48.
   PubMed Web of Science ®Google Scholar
• Palacios T, Stillman L, Borish L, et al. Lack of basophil CD203c-upregulating activity as an immunological marker to predict response to treatment with omalizumab in patients with symptomatic chronic urticaria. J Allergy Clin Immunol Pract. 2016;4:529–530.
   PubMed Web of Science ®Google Scholar
• Deza G, Bertolín-Colilla M, Pujol RM, et al. Basophil FcεRI expression in chronic spontaneous urticaria: a potential immunological predictor of response to omalizumab therapy. Acta Derm Venereol. 2017;97:698–704.
   PubMed Web of Science ®Google Scholar
• Asero R. Clinical variables of severe chronic spontaneous urticaria from total IgE standpoint: a retrospective study. Eur Ann Allergy Clin Immunol. 2022;54:30–33.
   PubMed Web of Science ®Google Scholar
• Gericke J, Metz M, Ohanyan T, et al. Serum autoreactivity predicts time to response to omalizumab therapy in chronic spontaneous urticaria. J Allergy Clin Immunol. 2017;139:1059–1061.
   PubMed Web of Science ®Google Scholar
• Endo T, Toyoshima S, Hayama K, et al. Relationship between changes in the 7-day urticaria activity score after treatment with omalizumab and the responsiveness of basophils to FcεRI stimulation in patients with chronic spontaneous urticaria Asia Pac Allergy. Asia Pac Allergy. 2020;10:e12.
   PubMed Web of Science ®Google Scholar
• Ertaş R, Hawro T, Altrichter S, et al. Antinuclear antibodies are common and linked to poor response to omalizumab treatment in patients with CSU. Allergy. 2020;75:468–470.
   PubMed Web of Science ®Google Scholar
• Schoepke N, Asero R, Ellrich A, et al. Biomarkers and clinical characteristics of autoimmune chronic spontaneous urticaria: results of the PURIST Study. Allergy. 2019;74:2427–2436.
   PubMed Web of Science ®Google Scholar
• Asero R. Omalizumab in severe chronic urticaria: are slow and non-responders different? Eur Ann Allergy Clin Immunol. 2021;53:263–266.
   PubMed Web of Science ®Google Scholar
• Maggi L, Rossettini B, Montaini G, et al. Omalizumab dampens type 2 inflammation in a group of long-term treated asthma patients and detaches IgE from FcεRI. Eur J Immunol. 2018;48:2005–2014.
   PubMed Web of Science ®Google Scholar
• Kaplan AP, Gimenez-Arnau AM, Saini SS. Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria. Allergy. 2017;72:519–533.
   PubMed Web of Science ®Google Scholar
• Maurer M, Khan DA, Komi DEA, et al. Biologics for the use in chronic spontaneous urticaria: when and which. J Allergy Clin Immunol Pract. 2021;9:1067–1078.
   PubMed Web of Science ®Google Scholar
• Tedeschi A, Kolkhir P, Asero R, et al. Chronic urticaria and coagulation: pathophysiological and clinical aspects. Allergy. 2014;69:683–691.
   PubMed Web of Science ®Google Scholar
• Yanase Y, Matsuo Y, Takahagi S, et al. Coagulation factors induce human skin mast cell and basophil degranulation via the activation of complement 5 and the C5a receptor. J Allergy Clin Immunol. 2021;147:1101–1104.
   PubMed Web of Science ®Google Scholar
• Shtessel M, Limjunyawong N, Oliver ET, et al. MRGPRX2 activation causes increased skin reactivity in patients with chronic spontaneous urticaria. J Invest Dermatol. 2021;141:678–681.
   PubMed Web of Science ®Google Scholar
• Cao TBT, Cha HY, Yang EM, et al. Elevated MRGPRX2 levels related to disease severity in patients with chronic spontaneous urticaria. Allergy Asthma Immunol Res. 2021;13:498–506.
   PubMed Web of Science ®Google Scholar
• Maurer M, Gimenez-Arnau AM, Sussman G, et al. Ligelizumab for chronic spontaneous urticaria. N Engl J Med. 2019;381:1321–1332.
   PubMed Web of Science ®Google Scholar
• Gasser P, Tarchevskaya SS, Guntern P, et al. The mechanistic and functional profile of the therapeutic anti-IgE antibody ligelizumab differs from omalizumab. Nat Commun. 2020;11:165.
   PubMed Web of Science ®Google Scholar
• Wedi B. Emerging treatments for chronic urticaria. Expert Opin Investig Drugs. 2022;31:281–290.
   PubMed Web of Science ®Google Scholar
• Harris JM, Cabanski CR, Scheerens H, et al. A randomized trial of quilizumab in adults with refractory chronic spontaneous urticaria. J Allergy Clin Immunol. 2016;138:1730–1732.
   PubMed Web of Science ®Google Scholar
• Asero R, Cugno M, Tedeschi A. Eosinophils in chronic urticaria: supporting or leading actors? World Allergy Organ J. 2009;2:213–217.
   PubMedGoogle Scholar
• Giménez-Arnau AM, DeMontojoye L, Asero R, et al. The pathogenesis of chronic spontaneous urticaria: the role of infiltrating cells. J Allergy Clin Immunol Pract. 2021;9:2195–2208.
   PubMed Web of Science ®Google Scholar
• Bernstein JA, Singh U, Rao MB, et al. Benralizumab for chronic spontaneous urticaria. N Engl J Med. 2020;383:1389–1391.
   PubMed Web of Science ®Google Scholar
• Magerl M, Terhorst D, Metz M, et al. Benefit of mepolizumab treatment in a patient with chronic spontaneous urticaria. J Dtsch Dermatol Ges. 2018;16:477–478.
   PubMed Web of Science ®Google Scholar
• Antonicelli L, Tontini C, Garritani MS, et al. Efficacy of mepolizumab in patients with concomitant severe eosinophilic asthma and severe chronic urticaria: an example of personalized medicine? J Investig Allergol Clin Immunol. 2021 Nov;29. Online ahead of print
   Google Scholar
• Maurer M, Altrichter S, Metz M, et al. Benefit from reslizumab treatment in a patient with chronic spontaneous urticaria and cold urticaria. J Eur Acad Dermatol Venereol. 2018;32:e112–3.
   PubMed Web of Science ®Google Scholar
• Sanchez J, Sanchez A, Muner M, et al. Presence of IgE autoantibodies against eosinophil peroxidase and eosinophil cationic protein in severe chronic spontaneous urticaria and atopic dermatitis. Allergy Asthma Immunol Res. 2021;13:746–761.
   PubMed Web of Science ®Google Scholar
• Maurer M, Casale T, Saini S, et al. Dupilumab significantly reduces itch and hives in patients with chronic spontaneous urticaria: results from a phase III trial (LIBERTY-CSU CUPID Study A). J Allergy Clin Immunol. 2022 ;149:AB312.
   Web of Science ®Google Scholar
• Hamilton JD, Harel S, Swanson BN, et al. Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases. Clin Exp Allergy. 2021;51:915–931.
   PubMed Web of Science ®Google Scholar
• Alvarado D, Maurer M, Gedrich R, et al. Anti-KIT monoclonal antibody CDX-0159 induces profound and durable mast cell suppression in a healthy volunteer study. Allergy. 2022 Feb 19;77(8):2393–2403. Online ahead of print.
   PubMed Web of Science ®Google Scholar
• Terhorst-Molawi D, Hawro T, Grekowitz E, et al. The anti-KIT antibody, CDX-0159, reduces mast cell numbers and circulating tryptase and improves disease control in patients with chronic inducible urticaria (CIndU). J Allergy Clin Immunol. 2022;149(2):AB178. AB178.
   Web of Science ®Google Scholar
• Altrichter S, Staubach P, Pasha M, et al. An open-label, proof-of-concept study of lirentelimab for antihistamine-resistant chronic spontaneous and inducible urticaria. J Allergy Clin Immunol. 2022;149:1683–1690.
   PubMed Web of Science ®Google Scholar
• Combalia A, Losno RA, Prieto-Gonzàlez S, et al. Rituximab in chronic spontaneous urticaria: an encouraging therapeutic approach. Skin Pharmacol Physiol. 2018;31:184–187.
   PubMed Web of Science ®Google Scholar
• Sabag DA, Matanes L, Bejar J, et al. Interleukin-17 is a potential player and treatment target in severe chronic spontaneous urticaria. Clin Exp Allergy. 2020;50:799–804.
   PubMed Web of Science ®Google Scholar
• Maul JT, Distler M, Kolios A, et al. Canakinumab lacks efficacy in treating adult patients with moderate to severe chronic spontaneous urticaria in a phase II randomized double-Blind placebo-Controlled single-center study. J Allergy Clin Immunol Pract. 2021;9:463–468.
   PubMed Web of Science ®Google Scholar
• Krause K, Weller K, Stefaniak R, et al. Efficacy and safety of the interleukin-1 antagonist rilonacept in Schnitzler syndrome: an open-label study. Allergy. 2012;67:943–950.
   PubMed Web of Science ®Google Scholar
• Kay AB, Clark P, Maurer M, et al. Elevations in T-helper-2-initiating cytokines (interleukin-33, interleukin-25 and thymic stromal lymphopoietin) in lesional skin from chronic spontaneous (‘idiopathic’) urticaria. Br J Dermatol. 2015;172:1294–1302.
   PubMed Web of Science ®Google Scholar
• Sand FI, Thomsen SF. Off-label use of TNF-alpha inhibitors in a dermatological university department: retrospective evaluation of 118 patients. Dermatol Ther. 2015;28:158–165.
   PubMed Web of Science ®Google Scholar
• Wilson LH, Eliason MJ, Leiferman KM, et al. Treatment of refractory chronic urticaria with tumor necrosis factor-alfa inhibitors. J Am Acad Dermatol. 2011;64:1221–1222.
   PubMed Web of Science ®Google Scholar
• Metz M, Sussman G, Gagnon R, et al. Fenebrutinib in H1 antihistamine-refractory chronic spontaneous urticaria: a randomized phase II trial. Nat Med. 2021;27:1961–1969.
   PubMed Web of Science ®Google Scholar
• Kolkhir P, Munoz M, Asero R, et al. Autoimmune chronic spontaneous urticaria. J Allergy Clin Immunol. 2022;149:1819–1831.
   PubMed Web of Science ®Google Scholar
• Maurer M, Berger W, Gimenez-Arnau A, et al. Remibrutinib, a novel BTK inhibitor, demonstrates promising efficacy and safety in chronic spontaneous urticaria. J Allergy Clin Immunol. In press;2022. DOI: 10.1016/j.jaci.2022.08.027.
   Google Scholar
• Asero R, Tedeschi A. Usefulness of a short course of oral prednisone in antihistamine-resistant chronic urticaria: a retrospective analysis. J Investig Allergol Clin Immunol. 2010;20:386–390.
   PubMed Web of Science ®Google Scholar
• Grattan CE, O’Donnell BF, Francis DM, et al. Randomized double-blind study of cyclosporin in chronic ‘idiopathic’ urticaria. Br J Dermatol. 2000;143:365–372.
   PubMed Web of Science ®Google Scholar
• Zhou B, Li J, Liu R, et al. The role of crosstalk of immune cells in pathogenesis of chronic spontaneous urticaria. Front Immunol. 2022;13:879754.
   PubMed Web of Science ®Google Scholar